University Center of Legal Medicine of Geneva, University of Geneva, Geneva, Switzerland.
World Health Organization, Geneva, Switzerland.
Int J Tuberc Lung Dis. 2020 May 1;24(5):57-60. doi: 10.5588/ijtld.17.0899.
Prisons are known to have extremely high tuberculosis (TB) and multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB prevalence and poor treatment outcomes. To examine the screening and M/XDR-TB treatment with new TB drugs in prisons from the perspective of international ethical and legal requirements. WHO recommendations on TB screening in prisons and M/XDR-TB treatment as well as the international human rights law on prisoners were analysed. Prisoners have a human right to access at least the same level of TB care as in their communities. Screening for TB in prisons, which may run contrary to a given individual's choice to be tested, may be justified by the positive obligation to prevent other prisoners from contracting a possibly deadly disease. Introduction of new TB drugs in prisons is necessary, ethically sound and should start in parallel with introduction in a civilian sector in strict compliance with the WHO recommendations. Access to screening for TB, as well as effective treatment according to WHO recommendations, must be ensured by countries on the basis of international human rights conventions.
监狱已知具有极高的结核病 (TB) 和耐多药 (MDR) 及广泛耐药 (XDR) TB 患病率和较差的治疗结果。从国际伦理和法律要求的角度来看，审查监狱中的新结核病药物筛查和 M/XDR-TB 治疗。分析了世卫组织关于监狱中的结核病筛查和 M/XDR-TB 治疗以及囚犯的国际人权法的建议。囚犯有权获得至少与他们所在社区相同水平的结核病护理。在监狱中进行结核病筛查，可能与个人接受检测的意愿相悖，但可以通过防止其他囚犯感染可能致命疾病的积极义务来证明是合理的。在监狱中引入新的结核病药物在道德上是合理的，并且必须在严格遵守世卫组织建议的情况下与在平民部门中的引入同时进行。各国必须根据国际人权公约确保对结核病进行筛查以及根据世卫组织建议进行有效治疗。
